Date: 17 June 2011
If one goes by the expectation of the stock market, there is no limit here. Piramal Glass, a listed glass company with a market cap of over Rs 1,000 crore, is considered as a deal in the pipeline.
Over the past one year, Piramal Glass shares rose 45% while the broader BSE 500 index rose only 5%.
“The market is looking at the track record and expects some transaction sooner or later,” an investment banker tracking mid-tier companies told Firstpost.
Piramal Healthcare, a company promoted by the Ajay Piramal Group, sold the flagship formulations business to Abbott Laboratories last year for Rs 17,500 crore ($3.2 billion).
Read more below.
www.firstpost.com
2011-06-17T13:00:00
Piramal Glass: Deal in the pipeline?
glassonweb.com 
Add new comment